Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Kite Pharma Part 5: Detailed Research That I Have Done In Coming to My Opinion on Kite (KITE, Avoid, $$54.06)

Investment Opinion Kite will be reporting interim results of the phase 2, ZUMA-1 trial of its lead product KTE-C19 by the end of September. The most bullish analysts are projecting a very positive outcome in this trial that will result in approval in 2017 and sales of as much as $1 billion of sales by […]

«Older Posts
«Older Posts
Search Graphic